1. Search Result
Search Result
Results for "

homodimer

" in MedChemExpress (MCE) Product Catalog:

42

Inhibitors & Agonists

1

Screening Libraries

2

Fluorescent Dye

5

Peptides

2

Inhibitory Antibodies

1

Natural
Products

3

Antibodies

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-D0844
    Glutathione oxidized
    5+ Cited Publications

    L-Glutathione oxidized; GSSG; Oxiglutatione

    Endogenous Metabolite Reactive Oxygen Species (ROS) Metabolic Disease
    Glutathione oxidized (L-Glutathione oxidized) is produced by the oxidation of glutathione. Detoxification of reactive oxygen species is accompanied by production of glutathione oxidized. Glutathione oxidized can be used for the research of sickle cells and erythrocytes .
    Glutathione oxidized
  • HY-D0093
    Ethidium homodimer
    4 Publications Verification

    EthD-1

    DNA Stain Others
    Ethidium homodimer (EthD-1) is a high-affinity fluorescent nucleic acid dye commonly used to stain mammals, bacteria, yeast, and fungi. Ethidium homodimer binds to DNA or RNA, enhancing fluorescence more than 30 times. The Ethidium homodimer has a strong positive charge, so it cannot cross cell membranes and stain living cells; But the Ethidium homodimer can cross the disordered region of the dead cell membrane to reach the nucleus and embed the DNA double strand to produce red fluorescence. Therefore, Ethidium homodimer is a relatively sensitive nucleic acid stain that can accurately detect nucleic acids in solution or in decomposing cells. Ethidium homodimer binds DNA, Ex/Em=528/617 nm .
    Ethidium homodimer
  • HY-106723A
    AMP-PCP disodium
    2 Publications Verification

    HSP Cancer
    AMP-PCP disodium is an ATP analogue and can bind to Hsp90 N-terminal domain with a Kd value of 3.8 μM. AMP-PCP disodium binding favors the formation of the active homodimer of Hsp90 .
    AMP-PCP disodium
  • HY-15340
    LG100268
    5 Publications Verification

    LG268

    RAR/RXR Autophagy Metabolic Disease
    LG100268 (LG268) is a potent, selective and orally active retinoid X receptor (RXR) agonist with EC50 values of 4 nM, 3 nM, and 4 nM for RXR-α, RXR-β, and RXR-γ, respectively . LG100268 displays >1000-fold selectivity for RXR over RAR, the Ki values are 3.4 nM, 6.2 nM and 9.2 nM for RXR-α, RXR-β, and RXR-γ, respectively . LG100268 activates RXR homodimers to induce transcriptional activation. LG100268 can be used for the study of lung carcinogenesisy .
    LG100268
  • HY-107413

    BMS-649

    RAR/RXR Tyrosine Hydroxylase Cancer
    SR11237 (BMS-649) GMP is SR11237 (HY-107413) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SR11237 is a RXR activator and lipid metabolism regulator that promotes the differentiation of induced neural stem cells into dopaminergic (TH-positive) neurons. SR11237 induces transcriptional regulation of lipogenic genes and cholesterol transporters, increases glycosaminoglycan release, and elevates total cellular triglyceride levels. SR11237 promotes heterodimerization of RXR with Nurr1, thereby enhancing tyrosine hydroxylase expression and facilitating dopamine release. SR11237 produces a synergistic effect when used in combination with bFGF/EGF. SR11237 is mainly used in studies related to osteoarthritis and Parkinson's disease .
    SR11237
  • HY-116274
    BMS-8
    1 Publications Verification

    PD-1/PD-L1 Cancer
    BMS-8 inhibits the PD-1/PD-L1 interaction with IC50 of 7.2 μM. BMS-8, binds directly to PD-L1 and induces formation of PD-L1 homodimers, which in turn prevents the interaction with PD-1 .
    BMS-8
  • HY-108523

    UVI 2112

    RAR/RXR Metabolic Disease
    LG100754 (UVI 2112) is a RXR dimers modulater. LG100754 acts as a RXR:RXR homodimer antagonist, but functions as a agonist towards RXR:PPARα and RXR:PPARγ heterodimers. LG100754 is an insulin sensitizer that functions through RXR .
    LG100754
  • HY-D1773

    Fluorescent Dye DNA Alkylator/Crosslinker Others
    YOYO-3 is a trimethine cyanine homodimer dye. YOYO-3 intercalates into AF488-tagged dsDNA molecules at the single-molecule level. YOYO-3 has a greater affinity for DNA than do EB and other Cyanine dyes .
    YOYO-3
  • HY-159768A

    Radionuclide-Drug Conjugates (RDCs) FAP Neurological Disease Cancer
    DOTAGA.Glu.(FAPi) 2 is a FAPI homodimer in which a central glutamic acid (Glu) linker connects FAPI and a chelator. Radiolabeled with gallium- 68, lutetium- 177 or terbium- 161, DOTAGA.Glu.(FAPi) 2 is applicable to FAP-positive cancer PET imaging studies. DOTAGA.Glu.(FAPi) 2 is suitable for research related to prostate adenocarcinoma and recurrent glioblastoma multiforme .
    DOTAGA.Glu.(FAPi)2
  • HY-E70715

    EGFR Cancer
    The erbB family comprises 4 structurally related receptors: ErbB1 (EGFR), ErbB2 (HER2-neu), ErbB3 and ErbB4. On ligand stimulation, the receptor forms either homodimers or heterodimers, which activate their cytoplasmic domain. ERBB2 775YVMA776 Recombinant Human Active Protein Kinase is a recombinant ERBB2 775YVMA776 protein that can be used to study ERBB2 775YVMA776-related functions .
    ERBB2 775YVMA776 Recombinant Human Active Protein Kinase
  • HY-106723

    HSP Cancer
    AMP-PCP is an ATP analogue and can bind to Hsp90 N-terminal domain with a Kd value of 3.8 μM. AMP-PCP binding favors the formation of the active homodimer of Hsp90 .
    AMP-PCP
  • HY-P10772

    Peptide-Drug Conjugates (PDCs) EBV Cancer
    L2P4 is a peptide-based and EBNA1 targeting fluorescent probe, which inhibits the EBNA1 homodimer formation and selectively inhibits EBV+ tumor growth. L2P4 exhibits cytotoxicity in EBV-positive C666-1 cell with LC50 of 46.4 μM .
    L2P4
  • HY-P10772A

    Peptide-Drug Conjugates (PDCs) EBV Cancer
    L2P4 TFA is a peptide-based and EBNA1 targeting fluorescent probe, which inhibits the EBNA1 homodimer formation and selectively inhibits EBV+ tumor growth. L2P4 TFA exhibits cytotoxicity in EBV-positive C666-1 cell with LC50 of 46.4 μM .
    L2P4 TFA
  • HY-168207

    Toll-like Receptor (TLR) NF-κB Inflammation/Immunology
    TH023 is an inhibitor for the TLR4 signaling pathway, that targets especially the formation of TLR4 homodimer. TH023 inhibits secreted embryonic alkaline phosphatase in cell HEK-Blue hTLR4 with an IC50 of 0.354 μM, and inhibits the NO expression in RAW264.7 with an IC50 of 1.61μM. TH023 also inhibits the activation of NF-κB, reduces the nuclear translocation of NF-κB p65. TH023 exhibits anti-inflammatory efficacy in LPS (HY-D1056)-induced mouse acute sepsis model, and ameliorates the mouse lung injury .
    TH023
  • HY-155539
    Cisd2 agonist 2
    1 Publications Verification

    IKZF Family Zinc Finger Protein Inflammation/Immunology
    Cisd2 agonist 2 (compound 6) is a Cisd2 activator (EC50=191 nM), and Cisd2 levels are associated with non-alcoholic fatty liver disease (NAFLD). Cisd2 agonist 2 has no significant in vivo toxicity in Cisd2hKO-het mice (heterozygous hepatocyte-specific Cisd2 knockout). Cisd2 (CDGSH iron sulfur domain 2) is a zinc finger protein that is mainly localized in the endoplasmic reticulum or mitochondrial membrane. Cisd2 participates in mitochondrial function by forming homodimers containing two redox-active 2Fe-2S clusters .
    Cisd2 agonist 2
  • HY-RS13559

    Small Interfering RNA (siRNA) Others

    SOD1 Human Pre-designed siRNA Set A contains three designed siRNAs for SOD1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SOD1 Human Pre-designed siRNA Set A
    SOD1 Human Pre-designed siRNA Set A
  • HY-P99772

    L19TNF

    TNF Receptor Cancer
    Onfekafusp alfa (L19TNF) is a homotrimer that forms from engineered peptides for the L19 antibody in scFv format fused to human TNF. Onfekafusp alfa can be used for malignant glioma research .
    Onfekafusp alfa
  • HY-178690

    MyD88 IFNAR Infection Inflammation/Immunology
    MyD88-IN-4 is a MyD88 inhibitor. MyD88-IN-4 exerts antiviral effects by up-regulating IFN-β, and anti-inflammatory effects by inhibiting pro-inflammatory cytokine production. MyD88-IN-4 prevents MyD88 homodimer formation and its interaction with IRF3/IRF7. MyD88-IN-4 demonstrates efficacy against encephalitic alphavirus infections by reducing viral replication and improving survival in VEEV TC-83-infected mouse models. MyD88-IN-4 can be used for the study of alphavirus infections, bacterial toxin-related diseases, and sepsis .
    MyD88-IN-4
  • HY-D1660

    NSC 219743

    DNA Stain Others
    Acridine homodimer (NSC 219743), acridine dimer, is a fluorescence dye. Acridine homodimer emits a blue-green fluorescence when bound to DNA. Acridine homodimer has extremely high affinity for AT-rich regions of nucleic acids, can be used for chromosome banding .
    Acridine homodimer
  • HY-P991091

    TNF Receptor Interleukin Related Inflammation/Immunology
    COVA322 is a bispecific TNF and IL-17A antibody. COVA322 inhibits simultaneously TNF and the IL-17A homodimer that can be used for the study of inflammatory diseases .
    COVA322
  • HY-159756B

    c-Myc Cancer
    KI-MS2-008 is a selective Max binder. KI-MS2-008 results in the stabilization of Max homodimers and the attenuation of Myc. KI-MS2-008 has anticancer activity against Myc-dependent cancer .
    KI-MS2-008
  • HY-P3223A

    Opioid Receptor Neurological Disease
    Biphalin acetate, a BBB-penetrable opioid peptide analog, contains two active enkephalin pharmacophores.Biphalin acetate has high affinity for opioid receptors. Biphalin acetate shows analgesic effect in acute, neuropathic, and chronic animal pain models. Biphalin acetate is also an antiviral, antiproliferative, anti-inflammatory, and neuroprotective agent .
    Biphalin acetate
  • HY-163801

    Nuclear Hormone Receptor 4A/NR4A Neurological Disease
    Nurr1 agonist 9 (Compound 36) is an agonist for Nurr1 with an EC50 of 0.090 µM and a Kd of 0.17 µM. Nurr1 agonist 9 activates the Nurr1 homodimer (NurRE, EC50=0.094 µM) and the Nurr1-RXR heterodimer (DR5, EC50=0.165 µM). Nurr1 agonist 9 induces the expression of Nurr1-regulated tyrosine hydroxylase (TH) in organoid Parkinson's Disease model. Nurr1 agonist 9 is human brain endothelial cell barrier prmeable .
    Nurr1 agonist 9
  • HY-149536

    Potassium Channel Neurological Disease
    TWIK-1/TREK-1-IN-1 (compound 2a) is an inhibitor of the TWIK-related potassium channel (Potassium Channel) TREK-1. TREK-1 contains a two-pore domain potassium (K2p) channel that dimerizes into TREK-1 homodimer and TWIK-1/TREK-1 heterodimer, and is an important antidepressant target. TWIK-1/TREK-1-IN-3 targets TREK-1 homodimer and TWIK-1/TREK-1 heterodimer with IC50s of 9.36 μM and 14.6 μM, respectively, and has antidepressant-like effects .
    TWIK-1/TREK-1-IN-1
  • HY-149537

    Potassium Channel Neurological Disease
    TWIK-1/TREK-1-IN-2 (Compound 2g) is a TWIK-1/TREK-1 inhibitor. TWIK-1/TREK-1-IN-2 inhibits TREK-1 homodimer and TWIK-1/TREK-1 heterodimer with IC50s of 10.13 μM and 15.5 μM. TWIK-1/TREK-1-IN-2 is an antidepressant .
    TWIK-1/TREK-1-IN-2
  • HY-121736

    AGI-026

    Isocitrate Dehydrogenase (IDH) Neurological Disease
    AGI-12026 is brain-penetrant dual inhibitor of mutant IDH1 and 2. AGI-12026 shows partial inhibition of the IDH1-R132H homodimer as allosteric modulators. AGI-12026 has the potential for research of glioma .
    AGI-12026
  • HY-125690

    PACAP Receptor Cancer
    Thielocin B1 is a protein-protein interaction inhibitor of PAC3 homodimer .
    Thielocin B1
  • HY-174669

    mRNA Cancer
    Human HNF1A mRNA encodes the human HNF1 homeobox A (HNF1A) protein, a transcription factor that required for the expression of several liver-specific genes. HNF1A functions as a homodimer and binds to the inverted palindrome 5''-GTTAATNATTAAC-3''.
    Human HNF1A mRNA
  • HY-149538

    Potassium Channel Neurological Disease
    TWIK-1/TREK-1-IN-3 (compound 2h) is an inhibitor of TWIK-related potassium channel (Potassium Channel) TREK-1. TREK-1 contains a two-pore domain potassium (K2p) channel that dimerizes into TREK-1 homodimer and TWIK-1/TREK-1 heterodimer, and is an important antidepressant target. TWIK-1/TREK-1-IN-3 targets TREK-1 homodimer and TWIK-1/TREK-1 heterodimer with IC50s of 9.74 μM and 16.5 μM, respectively, and has antidepressant-like effects .
    TWIK-1/TREK-1-IN-3
  • HY-126743

    Proteasome Others
    JBIR-22 is a protein-protein interaction inhibitor of proteasome assembly factor 3 homodimer, which has the activity of inhibiting this interaction and exerting long-term cytotoxicity against human cervical cancer cell lines, and its stereochemical structure has been determined by total synthesis.
    JBIR-22
  • HY-174662

    mRNA Inflammation/Immunology
    Human IFNG mRNA encodes the human interferon gamma (IFNG) protein, a member of the type II interferon class. IFNG is secreted by cells of both the innate and adaptive immune systems. The active protein is a homodimer that binds to the interferon gamma receptor which triggers a cellular response to viral and microbial infections.
    Human IFNG mRNA
  • HY-P3223

    Opioid Receptor Neurological Disease
    Biphalin TFA, a BBB-penetrable opioid peptide analog, contains two active enkephalin pharmacophores. Biphalin TFA has high affinity for opioid receptors. Biphalin TFA shows analgesic effect in acute, neuropathic, and chronic animal pain models. Biphalin TFA is also an antiviral, antiproliferative, anti-inflammatory, and neuroprotective agent .
    Biphalin TFA
  • HY-15340R

    LG268 (Standard)

    RAR/RXR Autophagy Reference Standards Metabolic Disease
    LG100268 (Standard) is the analytical standard of LG100268. This product is intended for research and analytical applications. LG100268 (LG268) is a potent, selective and orally active retinoid X receptor (RXR) agonist with EC50 values of 4 nM, 3 nM, and 4 nM for RXR-α, RXR-β, and RXR-γ, respectively . LG100268 displays >1000-fold selectivity for RXR over RAR, the Ki values are 3.4 nM, 6.2 nM and 9.2 nM for RXR-α, RXR-β, and RXR-γ, respectively . LG100268 activates RXR homodimers to induce transcriptional activation. LG100268 can be used for the study of lung carcinogenesisy .
    LG100268 (Standard)
  • HY-180336

    MyD88 Toll-like Receptor (TLR) NF-κB Collagen TGF-β Receptor p38 MAPK Reactive Oxygen Species (ROS) Metabolic Disease Inflammation/Immunology
    LM9 is a potent, orally active MyD88 inhibitor. LM9 blocks TLR4/MyD88 binding, MyD88 homodimer formation, and TLR4/MyD88/NF-κB signaling pathway activation. LM9 prevents atherosclerosis by regulating inflammatory responses and oxidative stress in macrophages. LM9 efficiently mitigates inflammatory responses and fibrosis in obesity-induced cardiomyopathy. LM9 can be used for fibrosis and atherosclerosis research .
    LM9
  • HY-E71291

    Biochemical Assay Reagents Others
    β-Enolase, Human is one of the three enolase isoenzymes found in mammals. This isoenzyme, a homodimer, is found in skeletal muscle cells in the adult.
    β-Enolase, Human
  • HY-E70923

    Biochemical Assay Reagents Metabolic Disease
    Xanthine dehydrogenase, Microorganism (EC 1.17.1.4) belongs to the molybdenum-containing hydroxylase family and participates in the oxidative metabolism of purines. Xanthine dehydrogenase, Microorganism (EC 1.17.1.4) is a homodimer and can be converted into xanthine oxidase through reversible thiol oxidation or irreversible proteolytic modification.
    Xanthine dehydrogenase, Microorganism
  • HY-107413R

    BMS-649 (Standard)

    Reference Standards RAR/RXR Tyrosine Hydroxylase Neurological Disease Inflammation/Immunology
    SR11237 (Standard) is the analytical standard of SR11237 (HY-107413). This product is intended for research and analytical applications. SR11237 is a RXR activator and lipid metabolism regulator that promotes the differentiation of induced neural stem cells into dopaminergic (TH-positive) neurons. SR11237 induces transcriptional regulation of lipogenic genes and cholesterol transporters, increases glycosaminoglycan release, and elevates total cellular triglyceride levels. SR11237 promotes heterodimerization of RXR with Nurr1, thereby enhancing tyrosine hydroxylase expression and facilitating dopamine release. SR11237 produces a synergistic effect when used in combination with bFGF/EGF. SR11237 is mainly used in studies related to osteoarthritis and Parkinson's disease .
    SR11237 (Standard)
  • HY-P2893C

    Biochemical Assay Reagents Metabolic Disease
    Creatinase, Flavobacterium sp. (EC 3.5.3.3) belongs to the hydrolase family and acts on carbon-nitrogen bonds other than peptide bonds, especially in linear amidine compounds. Creatinase, Flavobacterium sp. (EC 3.5.3.3) accelerates the conversion of creatine and water molecules into sarcosine and urea. Creatinase, Flavobacterium sp. (EC 3.5.3.3) functions as a homodimer.
    Creatinase, Flavobacterium sp.
  • HY-108523R

    UVI 2112 (Standard)

    Reference Standards RAR/RXR Metabolic Disease
    LG100754 (Standard) is the analytical standard of LG100754 (HY-108523). This product is intended for research and analytical applications. LG100754 (UVI 2112) is a RXR dimers modulater. LG100754 acts as a RXR:RXR homodimer antagonist, but functions as a agonist towards RXR:PPARα and RXR:PPARγ heterodimers. LG100754 is an insulin sensitizer that functions through RXR .
    LG100754 (Standard)
  • HY-180576

    Nuclear Hormone Receptor 4A/NR4A RAR/RXR Neurological Disease
    Nurr1/RXR dual agonist 1 is a dual activator of Nurr1 (EC50 = 2.6 µM) and RXR with K s of 0.6 and 1.1 µM, respectively. Nurr1/RXR dual agonist 1 exclusively activates the heterodimer response element DR5 by selectively destabilizing the Nurr1 homodimer and stabilizing the Nurr1:RXR heterodimer. Nurr1/RXR dual agonist 1 enhances expression of a specific subset of neuroprotective Nurr1 target genes while avoiding induction of genes associated with potential off-target effects in neuronal cells. Nurr1/RXR dual agonist 1 can be used for neurodegenerative diseases research .
    Nurr1/RXR agonist 1
  • HY-181588

    Nuclear Hormone Receptor 4A/NR4A Neurological Disease Inflammation/Immunology
    NR4A agonist-2 is a selective pan-NR4A agonist designed based on Vidofludimus (HY-14908), with a Kd of 0.10 μM against NR4A1, and EC50 values of 0.098 μM, 0.092 μM and 0.09 μM against Nur77, Nurr1, NOR-1, respectively. NR4A agonist-2 exhibits 47-fold selectivity over DHODH, and shows no cytotoxic activity at concentrations up to 10 μM. By binding to a specific surface pocket in the ligand-binding domain of Nurr1, NR4A agonist-2 inhibits the formation of Nurr1 homodimers, activates response elements such as NBRE, NurRE, DR5, and then potently induces the expression of neuroprotective genes including BDNF, SOD2, thereby exerting neuroprotective activity. NR4A agonist-2 can be used in the research of neurodegenerative diseases such as Parkinson's disease, dementia and multiple sclerosis .
    NR4A agonist-2
  • HY-181827

    Interleukin Related Inflammation/Immunology
    IL-17-IN-7 (Compound 23) is a IL-17 inhibitor with a pIC50 of 7.1 against IL-17A .
    IL-17-IN-7

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: